Loading clinical trials...
Loading clinical trials...
Reboxetine for Obstructive Sleep Apnoea After Upper Airway Surgery: a Randomised, Double-blind, Placebo-controlled Study
This pilot study will establish the feasibility of a larger trial to investigate whether reboxetine, a medication used to treat depression, can reduce the severity of obstructive sleep apnea (OSA) including increased blood oxygenation in post-surgical OSA patients where positive airway pressure (CPAP) therapy is either frequently poorly tolerated or not an option immediately post surgery. In this randomized, placebo-controlled, double-blind study, participants will use at-home sleep monitoring equipment before and after surgery plus measures of oxygenation. They will be prescribed either reboxetine or a placebo for seven days after surgery and complete questionnaires at the beginning and end of the study.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Flinders, Private and Public Hospitals and Flinders University
Bedford Park, South Australia, Australia
Start Date
August 10, 2023
Primary Completion Date
July 1, 2025
Completion Date
July 1, 2025
Last Updated
October 3, 2024
20
ESTIMATED participants
Reboxetine 4 MG Oral Tablet
DRUG
Placebo
DRUG
Lead Sponsor
Flinders University
Collaborators
NCT07446634
NCT07191314
NCT05497180
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions